Search results for "Neoplastic"

showing 10 items of 2901 documents

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.

2019

Background/aim Pineoblastoma of the adult age is an uncommon tumor with only 200 cases reported. A standardized approach for an optimal adjuvant strategy is currently lacking. The case presented herein also deals with the issue of central nervous system tumors in pregnancy. Case report A 21-year-old pregnant woman presented with massive hydrocephalus due to a mass in the pineal region detected with MRI. After positioning an urgent ventricular derivation, a cesarean section was performed. During a third ventriculocisternostomy, a biopsy revealed a pineoblastoma. After a maximal safe resection, postoperative craniospinal irradiation for a total dose of 36 Gy plus a sequential boost to the tum…

AdultCancer Researchmedicine.medical_specialtyVincristinePineal GlandCraniospinal IrradiationVentriculostomy03 medical and health sciences0302 clinical medicinePregnancyBiopsyMedicineHumansPineoblastomaPregnancymedicine.diagnostic_testbusiness.industryCesarean SectionGestational ageGeneral MedicineChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingHydrocephalusAdult PineoblastomaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologybusinessPinealomaPregnancy Complications Neoplasticmedicine.drugAnticancer research
researchProduct

Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy – A technique in its infancy but already successful in fe…

2008

Increasing survival rates in young cancer patients, new reproductive techniques and the growing interest in quality of life after gonadotoxic cancer therapies have placed fertility preservation as an important issue to oncologists, fertility specialists and patients. Several techniques are now available for fertility preservation in these patients. A new promising method is cryopreservation and transplantation of ovarian cortex. Ovarian tissue can be extracted by laparoscopy without any significant delay of gonadotoxic therapy. The tissue can be cryopreserved by specialised centres of reproductive medicine and transplanted in case the women experience premature ovarian failure (POF). This r…

AdultCancer Researchmedicine.medical_specialtyendocrine system diseasesOvarian Cortexmedia_common.quotation_subjectReproductive medicineAntineoplastic AgentsFertilityTissue BanksPrimary Ovarian InsufficiencymedicineHumansOvarian tissue cryopreservationFertility preservationIntensive care medicinemedia_commonCryopreservationOvarian Neoplasmsbusiness.industryOvarymedicine.diseaseSurgeryPremature ovarian failureTransplantationFertilityOncologyTissue bankFemalebusinessEuropean Journal of Cancer
researchProduct

Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck ca…

1989

A group of 23 consecutive patients with biopsy-proven advanced or metastatic head and neck cancer were treated with cisplatinum, 100 mg/m2 i.v., on day 1 plus 5-fluorouracil, 1000 mg/m2, in continuous infusion for 5 days. Most patients (87%) had recurrent or metastatic cancer and were previously treated (78%). Out of 21 evaluable patients we obtained a 42% overall response rate (complete + partial responses) with a mean duration of more than 8 months and a 14% minimal response rate. A stabilization of disease was achieved in 28% of cases, while 14% of patients progressed. This response rate, as well as the duration of response, seems to be similar to those obtained in other series comprisin…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyMetastasisInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisInfusions IntravenousAgedResponse rate (survey)ChemotherapyHematologybusiness.industryHead and neck cancerCancerGeneral MedicineMiddle Agedmedicine.diseaseSurgeryOncologyFluorouracilHead and Neck NeoplasmsToxicityFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct

Lifestyle changes in cancer patients undergoing curative or palliative chemotherapy: is it feasible?

2017

This study aimed to explore the feasibility of an individualized comprehensive lifestyle intervention in cancer patients undergoing curative or palliative chemotherapy.At one cancer center, serving a population of 180,000, 100 consecutive of 161 eligible newly diagnosed cancer patients starting curative or palliative chemotherapy entered a 12-month comprehensive, individualized lifestyle intervention. Participants received a grouped startup course and monthly counseling, based on self-reported and electronically evaluated lifestyle behaviors. Patients with completed baseline and end of study measurements are included in the final analyses. Patients who did not complete end of study measurem…

AdultCounselingMalemedicine.medical_specialtyMEDLINEAntineoplastic Agents03 medical and health sciences0302 clinical medicineFeeding behaviorNeoplasmsLifestyle interventionmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineExerciseAgedbusiness.industryCancerHematologyGeneral MedicinePalliative chemotherapyFeeding BehaviorMiddle Agedmedicine.diseaseClinical trialOncology030220 oncology & carcinogenesisFeasibility StudiesFemalebusinessRisk Reduction BehaviorActa oncologica (Stockholm, Sweden)
researchProduct

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Activity of the antiestrogenic cajanin stilbene acid towards breast cancer

2014

Antiestrogenic therapy is a mainstay for estrogen receptor (ERα)-positive breast cancer. Due to the development of resistance to established antihormones such as tamoxifen, novel compounds are required. The low abundant cajanin stilbene acid (CSA) recently isolated by us from Pigeon Pea (Cajanus cajan) has structural similarities with estrogen. We analyzed the cytotoxic and anticancer activity of CSA in ERα-positive and -negative human breast cancer cells in vitro, in vivo and in silico. CSA exerts anticancer and antiestrogenic activities towards ERα-positive breast cancer, and it showed cytotoxicity towards tamoxifen-resistant MCF-7 cells, implying that CSA may be active against tamoxifen-…

AdultEndocrinology Diabetes and MetabolismClinical BiochemistryMice NudeEstrogen receptorBreast NeoplasmsPharmacologyBiochemistryBreast cancerCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsStilbenesAnimalsHumansMedicineCytotoxic T cellPromoter Regions Geneticskin and connective tissue diseasesCytotoxicityMolecular BiologyNutrition and Dieteticsbusiness.industryEstrogen AntagonistsEstrogen Receptor alphaCancerMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysSalicylatesGene Expression Regulation NeoplasticTamoxifenReceptors EstrogenCancer cellMCF-7 CellsFemalebusinessEstrogen receptor alphaTamoxifenmedicine.drugThe Journal of Nutritional Biochemistry
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

2009

A novel cancer stem-like cell line (3AB-OS), expressing a number of pluripotent stem cell markers, was irreversibly selected from human osteosarcoma MG-63 cells by long-term treatment (100 days) with 3-aminobenzamide (3AB). 3AB-OS cells are a heterogeneous and stable cell population composed by three types of fibroblastoid cells, spindle-shaped, polygonal-shaped, and rounded-shaped. With respect to MG-63 cells, 3AB-OS cells are extremely smaller, possess a much greater capacity to form spheres, a stronger self-renewal ability and much higher levels of cell cycle markers which account for G1-S/G2-M phases progression. Differently from MG-63 cells, 3AB-OS cells can be reseeded unlimitedly wit…

AdultHomeobox protein NANOGAdolescentPhysiologyCellular differentiationClinical BiochemistryApoptosisBiologyStem cell markerYoung Adultcancer stemm cells osteosarcoma PARP inhibitorsCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaHumansRhodamine 123Enzyme InhibitorsProgenitor cellChildInduced pluripotent stem cellCell ShapeCell potencyFluorescent DyesOsteosarcomaCell DifferentiationCell BiologyCalcium Channel BlockersDrug Resistance MultipleGene Expression Regulation NeoplasticVerapamilBenzamidesImmunologyNeoplastic Stem CellsCancer researchATP-Binding Cassette TransportersBenzimidazolesStem cellBiomarkersJournal of Cellular Physiology
researchProduct